Yasumoto R, Asakawa M, Kakinoki K, Umeda M, Yoshimoto M, Kawashima H, Tanabe S, Nishisaka N, Kishimoto T
Department of Urology, Osaka City University Medical School.
Hinyokika Kiyo. 1988 Sep;34(9):1669-73.
Eighteen patients with renal hypertension were treated with metoprolol (Seloken) for more than 3 months. Compared with the pretreatment value, the mean blood pressure decreased by 6.0, 11.2, 9.2 and 12.2 mmHg, after 2 weeks and 3, 6 and 12 months of treatment with metoprolol, respectively. All the differences observed were statistically significant (p less than 0.01). The blood pressure lowering effect of metoprolol was observed in 12 of the 17 patients (70.6%) examined. Decrease in plasma renin activity was seen in most of the responders. Although the number of patients was limited, the plasma level of metoprolol was also measured. The results indicated no sign of accumulation of metoprolol in the body. Moderate deterioration in renal function was observed in 1 patient but the treatment with metoprolol could be continued. Metoprolol administration had to be discontinued in 1 patient, who developed asthma. There were no other serious side effects.
18例肾性高血压患者接受美托洛尔（倍他乐克）治疗超过3个月。与治疗前值相比，在使用美托洛尔治疗2周以及3、6和12个月后，平均血压分别下降了6.0、11.2、9.2和12.2 mmHg。观察到的所有差异均具有统计学意义（p小于0.01）。在接受检查的17例患者中的12例（70.6%）观察到了美托洛尔的降压效果。大多数有反应者的血浆肾素活性降低。尽管患者数量有限，但也测定了美托洛尔的血浆水平。结果表明体内没有美托洛尔蓄积的迹象。1例患者出现肾功能中度恶化，但美托洛尔治疗可以继续。1例出现哮喘的患者不得不停止使用美托洛尔。没有其他严重的副作用。
